Impact of Atrial Fibrillation on Heart Failure in Patients Treated With Anthracycline Chemotherapy.

Abstract

Atrial fibrillation (AF) and anthracyclines are known risk factors for heart failure (HF). The magnitude of the effect of preexisting AF (preanthracycline AF) and newly developed AF (postanthracycline AF) in patients treated with anthracyclines on the occurrence of HF is unknown. The aim of our study was to characterize the impact of preanthracycline and postanthracycline AF on the subsequent occurrence of HF in patients treated with anthracyclines. In 5,598 patients treated with new anthracycline therapy at a tertiary center between 2008 and 2021, propensity score matching was used to match 204 pairs with or without preanthracycline AF and 135 pairs with or without postanthracycline AF. The primary outcome was new-onset symptomatic HF defined by the American Heart Association/American College of Cardiology guidelines. Patients with and without preanthracycline and postanthracycline AF were well matched for age, gender, medications, and cardiovascular risk factors. A total of 45 patients with preanthracycline AF and 23 matched patients developed HF (5-year cumulative incidence: 29% in the preanthracycline AF group and 13% in the matched group, p = 0.003; hazard ratio 2.1, 95% confidence interval 1.3 to 3.4, p = 0.004). A total of 161 patients (2.9%) developed postanthracycline AF. A total of 39 patients (5-year cumulative incidence: 40%) with postanthracycline AF and 9 matched patients (5-year cumulative incidence: 7%) developed HF (hazard ratio 6.1, 95% confidence interval 3.0 to 12.4, p <0.001). Preanthracycline AF and postanthracycline AF are associated with a high incidence of subsequent HF in patients treated with anthracyclines. Prospective studies of therapies are required to decrease HF in these high-risk patients.

• Authors: Takeshi Onoue, Yu Kang, Bénédicte Lefebvre, Amanda M Smith, Srinivas Denduluri, Michael G Fradley, Jesse Chittams, Joseph R Carver, Marielle Scherrer-Crosbie
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 211 Pg. 268-274 (Jan 15 2024) ISSN: 1879-1913 [Electronic] United States
• PMID: 37984640 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Anthracyclines
• Antibiotics, Antineoplastic

Topics

• Humans
• Atrial Fibrillation (drug therapy, epidemiology, complications)
• Prospective Studies
• Anthracyclines (adverse effects)
• Heart Failure (chemically induced, epidemiology, drug therapy)
• Risk Factors
• Antibiotics, Antineoplastic